SCHEDULE 13G/A: Perceptive Advisors and Affiliates Disclose 2.5% Passive Stake in CARGO Therapeutics
Beneficial Ownership Report (Schedule 13G Amendment)
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Xontogeny Venture Fund II, L.P. collectively reported a 2.5% beneficial ownership stake in CARGO Therapeutics, Inc. common stock as of April 23, 2025.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Xontogeny Venture Fund II, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in CARGO Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 1,170,810 shares of CARGO Therapeutics, Inc. Common Stock.
- This ownership represents 2.5% of the Issuer's outstanding Common Stock.
- The percentage is based on 46,052,368 shares of Common Stock outstanding, as reported by CARGO Therapeutics, Inc. in its Annual Form 10-K filed with the SEC on March 12, 2025.
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Xontogeny Venture Fund II, L.P. each hold shared voting and shared dispositive power over 1,170,810 shares.
- Perceptive Life Sciences Master Fund, Ltd. is also listed as a reporting person but holds 0.0% beneficial ownership and no voting or dispositive power over the shares reported by the other entities.
Sentiment
Score: 5
Explanation: The document is a factual report of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is a routine regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of passive beneficial ownership by an investment firm in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact of investment.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors, which can influence market perception of institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date CARGO Therapeutics, Inc. filed its Annual Form 10-K, reporting 46,052,368 shares of Common Stock outstanding. |
| 04/23/2025 | Date of event which requires the filing of this Schedule 13G Amendment No. 2. |
Keywords
CARGO Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13G, beneficial ownership, common stock, investment, passive stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.